Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "disease"

3231 News Found

Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial
Clinical Trials | February 14, 2026

Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial

PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients


Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M
Medical Device | February 13, 2026

Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure


Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
News | February 13, 2026

Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer

KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components


Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion
News | February 10, 2026

Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion

The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles


India’s go-to diabetes test under scrutiny as new evidence flags major gaps
R&D | February 10, 2026

India’s go-to diabetes test under scrutiny as new evidence flags major gaps

The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings


DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
News | February 09, 2026

DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments


Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
News | February 09, 2026

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution


Biomica seals exclusive global license for groundbreaking microbiome cancer therapy
News | February 09, 2026

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer


Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients
Clinical Trials | February 07, 2026

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing